Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)

NCT05162027 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT05162027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Terminated
Start date
May 26, 2022
Completion date
January 3, 2023
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

temporomandibular disorders